In this phase 2 clinical trial, the authors assess protective efficacy of a Plasmodium vivax circumsporozoite vaccine in naïve and semi-immune individuals from controlled human malaria infection as well as antibody and IFN-γ response to vaccination.
- Myriam Arévalo-Herrera
- Xiomara Gaitán
- Sócrates Herrera